Skip to content

GREENWICH LIFESCIENCES, INC.: 10-K filed 2023-03-31

What GREENWICH LIFESCIENCES, INC. reported in its annual report filed 2023-03-31 (fiscal FY 2022): 20 published measures, 38 facts as tagged in accession 0001493152-23-010284.

This filing

Form
10-K (annual report)
Filed
2023-03-31
Fiscal period
fiscal FY 2022
Accession
0001493152-23-010284 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All GREENWICH LIFESCIENCES, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2022-12-3113,477,029USD
At 2021-12-3127,216,884USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2022-12-31262,905USD
At 2021-12-31385,172USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2022-12-3113,214,124USD
At 2021-12-3126,831,712USD
At 2020-12-3127,631,110USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2022-12-3113,468,026USD
At 2021-12-3127,204,269USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2022-01-01 to 2022-12-31-7,825,237USD365
2021-01-01 to 2021-12-31-4,570,576USD365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2022-01-01 to 2022-12-31-6,200,027USD365
2021-01-01 to 2021-12-31-4,291,548USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2022-01-01 to 2022-12-31-7,536,216USD365
2021-01-01 to 2021-12-312,835,442USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2022-12-31-41,472,766USD
At 2021-12-31-33,647,529USD

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2022-01-01 to 2022-12-31-0.61USD/shares365
2021-01-01 to 2021-12-31-0.35USD/shares365

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2022-01-01 to 2022-12-311,743,865USD365
2021-01-01 to 2021-12-31660,582USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2022-01-01 to 2022-12-31-8,040,254USD365
2021-01-01 to 2021-12-31-4,597,943USD365

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2022-12-31262,905USD
At 2021-12-31385,172USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2022-12-319,003USD
At 2021-12-3112,615USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2022-01-01 to 2022-12-317,536,216USD365

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2022-01-01 to 2022-12-318,040,254USD365
2021-01-01 to 2021-12-314,597,943USD365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2022-01-01 to 2022-12-316,475,668USD365
2021-01-01 to 2021-12-313,559,515USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2022-12-3112,848,165shares
At 2021-12-3113,147,829shares

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2022-01-01 to 2022-12-311,564,586USD365
2021-01-01 to 2021-12-311,038,428USD365

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2021-01-01 to 2021-12-313,110,596USD365

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2021-01-01 to 2021-12-31-526,732USD365

Inspect the source

Entity
GREENWICH LIFESCIENCES, INC. / CIK 0001799788
Captured
2026-09-21T17:27:54.821Z
SEC response SHA-256
a617dbe92932ff09e9921f2bebe266085b6d33d46c3d873a6ff42dd23172a3bb

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001799788.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))